For patients living with chronic Hepatitis B, a specific question now has both a new answer and a new urgency: do you also have Hepatitis Delta?
On May 22, 2026, the FDA approved bulevirtide-gmod injection (Hepcludex; Gilead Sciences) as the first-ever treatment for chronic Hepatitis Delta Virus (HDV) infection in the United States. The approval is for adults without cirrhosis or with compensated cirrhosis, under the FDA's Accelerated Approval pathway.
